Inflammation drives alternative first exon usage to regulate immune genes including a novel iron regulated isoform of Aim2

Abstract

Determining the layers of gene regulation within the innate immune response is critical to our understanding of the cellular responses to infection and dysregulation in disease. We identified a conserved mechanism of gene regulation in human and mouse via changes in alternative first exon (AFE) usage following inflammation, resulting in changes to isoform usage. Of these AFE events, we identified 50 unannotated transcription start sites (TSS) in mice using Oxford Nanopore native RNA sequencing, one of which is the cytosolic receptor for dsDNA and known inflammatory inducible gene, Aim2. We show that this unannotated AFE isoform of Aim2 is the predominant isoform transcribed during inflammation and contains an iron-responsive element in its 5′UTR enabling mRNA translation to be regulated by iron levels. This work highlights the importance of examining alternative isoform changes and translational regulation in the innate immune response and uncovers novel regulatory mechanisms of Aim2.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE141754.

The following previously published data sets were used

Article and author information

Author details

  1. Elektra Kantzari Robinson

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  2. Pratibha Jagannatha

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0257-3139
  3. Sergio Covarrubias

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  4. Matthew Cattle

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  5. Valeriya Smaliy

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  6. Rojin Safavi

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  7. Barbara Shapleigh

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  8. Robin Abu-Shumays

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  9. Miten Jain

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  10. Suzanne M Cloonan

    Division of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, United States
    Competing interests
    No competing interests declared.
  11. Mark Akeson

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    Mark Akeson, holds options in Oxford Nanopore Technologies (ONT). MA is a paid consultant to ONT received reimbursement for travel, accommodation and conference fees to speak at events organized by ONT. MA is an inventor on 11 UC patents licensed to ONT (6,267,872, 6,465,193, 6,746,594, 6,936,433, 7,060,50, 8,500,982, 8,679,747, 9,481,908, 9,797,013, 10,059,988, and 10,081,835). MA received research funding from ONT..
  12. Angela N Brooks

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    For correspondence
    anbrooks@ucsc.edu
    Competing interests
    Angela N Brooks, received reimbursement for travel, accommodation and conference fees to speak at events organized by Oxford Nanopore Technologies (ONT)..
  13. Susan Carpenter

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    For correspondence
    sucarpen@ucsc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1427-3897

Funding

NIH Office of the Director (HG010053)

  • Angela N Brooks

Oxford Nanopore Technologies (SC20130149)

  • Mark Akeson

UCSC Committee on Research (COR)

  • Susan Carpenter

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal work was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee at the University of California Santa Cruz (Protocol number CARPS1810).

Copyright

© 2021, Robinson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,872
    views
  • 426
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elektra Kantzari Robinson
  2. Pratibha Jagannatha
  3. Sergio Covarrubias
  4. Matthew Cattle
  5. Valeriya Smaliy
  6. Rojin Safavi
  7. Barbara Shapleigh
  8. Robin Abu-Shumays
  9. Miten Jain
  10. Suzanne M Cloonan
  11. Mark Akeson
  12. Angela N Brooks
  13. Susan Carpenter
(2021)
Inflammation drives alternative first exon usage to regulate immune genes including a novel iron regulated isoform of Aim2
eLife 10:e69431.
https://doi.org/10.7554/eLife.69431

Share this article

https://doi.org/10.7554/eLife.69431

Further reading

    1. Genetics and Genomics
    Silvia Diz-de Almeida, Raquel Cruz ... Ángel Carracedo
    Research Article

    The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we conducted a genome-wide association study (GWAS) for COVID-19 hospitalization in admixed Americans, comprising a total of 4702 hospitalized cases recruited by SCOURGE and seven other participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and were first discovered in Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.

    1. Genetics and Genomics
    Jake D Lehle, Yu-Huey Lin ... John R McCarrey
    Research Article

    Endocrine disrupting chemicals (EDCs) such as bisphenol S (BPS) are xenobiotic compounds that can disrupt endocrine signaling due to steric similarities to endogenous hormones. EDCs have been shown to induce disruptions in normal epigenetic programming (epimutations) and differentially expressed genes (DEGs) that predispose disease states. Most interestingly, the prevalence of epimutations following exposure to many EDCs persists over multiple generations. Many studies have described direct and prolonged effects of EDC exposure in animal models, but many questions remain about molecular mechanisms by which EDC-induced epimutations are introduced or subsequently propagated, whether there are cell type-specific susceptibilities to the same EDC, and whether this correlates with differential expression of relevant hormone receptors. We exposed cultured pluripotent (iPS), somatic (Sertoli and granulosa), and primordial germ cell-like (PGCLC) cells to BPS and found that differential incidences of BPS-induced epimutations and DEGs correlated with differential expression of relevant hormone receptors inducing epimutations near relevant hormone response elements in somatic and pluripotent, but not germ cell types. Most interestingly, we found that when iPS cells were exposed to BPS and then induced to differentiate into PGCLCs, the prevalence of epimutations and DEGs was largely retained, however, >90% of the specific epimutations and DEGs were replaced by novel epimutations and DEGs. These results suggest a unique mechanism by which an EDC-induced epimutated state may be propagated transgenerationally.